{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:18:32Z","timestamp":1774009112726,"version":"3.50.1"},"reference-count":101,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Conventional allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment option for various hematological diseases due, in part to high-dose conditioning and, in part, to graft-versus-tumor effects. Reduced-intensity or non-myeloablative conditioning regimens have relied mostly on graft-versus-tumor effects for disease control, and their advent has allowed relatively older and medically infirm patients to be offered allo-HCT. However, both HCT modalities have been associated with organ toxicities and graft-versus-host disease, resulting in substantial non-relapse mortality. It has become increasingly important to optimize pre-transplant risk assessment in order to improve HCT decision making and clinical trial assignments. Single-organ comorbidity involving liver, lung, heart, or kidney before HCT has been traditionally found to cause organ toxicity after HCT. Recent efforts have resulted in the advent of a weighted scoring system that could sensitively capture multiple-organ comorbidities prior to HCT. The HCT-comorbidity index (HCT-CI) has provided better prediction of HCT-related morbidity and mortality than other non-HCT-specific indices. Subsequent studies, with the exception of a few studies with modest numbers of patients, have confirmed the prognostic importance of the HCT-CI. Further, the HCT-CI has been consolidated with various disease-specific and patient-specific risk factors to refine assignments of patients to the appropriate HCT setting. Ongoing studies are addressing prospective validation of the HCT-CI, furthering our understanding of biological aging, and enhancing the applicability of the HCT-CI comorbidity coding. Future knowledge of the impacts of multiple comorbidities on post-HCT toxicities might guide new prophylactic and therapeutic interventions to lessen the procedure's mortality.<\/jats:p>","DOI":"10.1182\/asheducation-2010.1.237","type":"journal-article","created":{"date-parts":[[2011,1,16]],"date-time":"2011-01-16T19:08:48Z","timestamp":1295204928000},"page":"237-247","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":50,"title":["Comorbidities and Hematopoietic Cell Transplantation Outcomes"],"prefix":"10.1182","volume":"2010","author":[{"given":"Mohamed L.","family":"Sorror","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"4","key":"2019111718012635900_B1","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood-2004-02-0545","article-title":"Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplant comorbidities","volume":"104","author":"Sorror","year":"2004","journal-title":"Blood"},{"issue":"5","key":"2019111718012635900_B2","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1182\/blood-2004-03-0804","article-title":"Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA matched related donors","volume":"104","author":"Diaconescu","year":"2004","journal-title":"Blood"},{"key":"2019111718012635900_B3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/0-306-47527-8_16","article-title":"Infection in hematopoietic stem cell transplantation","volume-title":"Clinical Approach to Infection in the Compromised Host","author":"Boeckh","year":"2002"},{"key":"2019111718012635900_B4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00001432-200208000-00001","article-title":"Infectious risks and outcomes after stem cell transplantation: are nonmyeloablative transplants changing the picture?","volume":"15","author":"Junghanss","year":"2002","journal-title":"Curr Opin Inf Dis"},{"issue":"20","key":"2019111718012635900_B5","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1182\/blood-2009-06-204669","article-title":"Acute graft-versus-host disease; from the bench to the bedside","volume":"114","author":"Soci\u00e9","year":"2009","journal-title":"Blood"},{"issue":"24","key":"2019111718012635900_B6","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1182\/blood-2008-10-161638","article-title":"The role of B cells in the pathogenesis of graft-versus-host disease","volume":"114","author":"Shimabukuro-Vornhagen","year":"2009","journal-title":"Blood"},{"key":"2019111718012635900_B7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bbmt.2007.10.023","article-title":"Chronic graft-versus-host disease: how can we release Prometheus?","volume":"14","author":"Teshima","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111718012635900_B8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1182\/asheducation-2008.1.125","article-title":"Late pulmonary, cardiovascular, and renal complications after hematopoietic stem cell transplantation and recommended screening practices","author":"Tichelli","year":"2008","journal-title":"Hematology"},{"issue":"12","key":"2019111718012635900_B9","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1182\/blood-2009-06-225631","article-title":"Long-term recovery after hematopoietic cell transplantation: predictors of quality-of-life concerns","volume":"115","author":"Wong","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2019111718012635900_B10","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.bbmt.2007.07.002","article-title":"Second malignancies after allogeneic hematopoietic cell transplantation","volume":"13","author":"Lowe","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2019111718012635900_B11","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/sj.bmt.1704267","article-title":"Are predictive factors clinically useful in bone marrow transplantation?","volume":"32","author":"Bolwell","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2019111718012635900_B12","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.bbmt.2004.10.008","article-title":"Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation","volume":"11","author":"Wong","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2019111718012635900_B13","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1182\/blood.V112.11.2162.2162","article-title":"Allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning for patients (pts) aged > or = to 60 years [Abstract]","volume":"112","author":"Sorror","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2019111718012635900_B14","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","article-title":"Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome","volume":"28","author":"McClune","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111718012635900_B15","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00432-007-0233-x","article-title":"Age, severe comorbidity and functional impairment independently contribute to poor survival in cancer patients","volume":"133","author":"Wedding","year":"2007","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"2019111718012635900_B16","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.ejca.2005.01.010","article-title":"Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry","volume":"41","author":"van Spronsen","year":"2005","journal-title":"Eur J Cancer"},{"issue":"3","key":"2019111718012635900_B17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0895-4356(02)00585-1","article-title":"How to measure comorbidity. a critical review of available methods","volume":"56","author":"de Groot","year":"2003","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"2019111718012635900_B18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.critrevonc.2008.01.013","article-title":"The changing prevalence of comorbidity across the age spectrum","volume":"67","author":"Piccirillo","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"2019111718012635900_B19","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1634\/theoncologist.8-6-541","article-title":"Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program","volume":"8","author":"Gloeckler Ries","year":"2003","journal-title":"Oncologist"},{"issue":"12","key":"2019111718012635900_B20","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111718012635900_B21","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1200\/JCO.1994.12.5.998","article-title":"Cardiac toxicity of bone marrow transplantation: Predictive value of cardiologic evaluation before transplant","volume":"12","author":"Hertenstein","year":"1994","journal-title":"J Clin Oncol"},{"key":"2019111718012635900_B22","first-page":"173","article-title":"Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: Risk for cardiac toxicity","volume":"5","author":"Bearman","year":"1990","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2019111718012635900_B23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/sj.bmt.1702783","article-title":"Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction","volume":"27","author":"Fujimaki","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"2019111718012635900_B24","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1378\/chest.101.5.1257","article-title":"Predictive value of pulmonary function tests before marrow transplantation","volume":"101","author":"Crawford","year":"1992","journal-title":"Chest"},{"key":"2019111718012635900_B25","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1378\/chest.102.5.1484","article-title":"Pretransplant pulmonary function predicts cytomegalovirus-associated interstitial pneumonia following bone marrow transplantation","volume":"102","author":"Horak","year":"1992","journal-title":"Chest"},{"issue":"3","key":"2019111718012635900_B26","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1164\/rccm.200502-212OC","article-title":"Pretransplant lung function, respiratory failure, and mortality after stem cell transplantation","volume":"172","author":"Parimon","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"2019111718012635900_B27","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1200\/JCO.1998.16.12.3796","article-title":"Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients","volume":"16","author":"Goldberg","year":"1998","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111718012635900_B28","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.bbmt.2006.07.016","article-title":"Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation","volume":"12","author":"Savani","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111718012635900_B29","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.bbmt.2005.01.003","article-title":"Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation","volume":"11","author":"Chien","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2019111718012635900_B30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Intern Med"},{"issue":"1","key":"2019111718012635900_B31","first-page":"75","article-title":"Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia","volume":"17","author":"Rozman","year":"1996","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2019111718012635900_B32","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/00004836-200305000-00013","article-title":"Causes and risk factors for liver injury following bone marrow transplantation","volume":"36","author":"Ozdogan","year":"2003","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"2019111718012635900_B33","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1159\/000168889","article-title":"Acute renal failure in patients following bone marrow transplantation: prevalence, risk factors and outcome","volume":"15","author":"Gruss","year":"1995","journal-title":"Am J Nephrol"},{"issue":"8","key":"2019111718012635900_B34","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1200\/JCO.2002.08.757","article-title":"Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases","volume":"20","author":"Loberiza","year":"2002","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111718012635900_B35","first-page":"78a","article-title":"Transplant-related toxicities (TRT) and mortality following HLA-matched unrelated donor hematopoietic cell transplantation (URD-HCT) using nonmyeloablative (NM) compared to myeloablative (M) conditioning: influence of pretransplant comorbidities [Abstract]","volume":"102","author":"Sorror","year":"2003","journal-title":"Blood"},{"issue":"5","key":"2019111718012635900_B36","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"16","key":"2019111718012635900_B37","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1200\/JCO.2005.04.569","article-title":"Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia","volume":"23","author":"Sorror","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111718012635900_B38","first-page":"708a","article-title":"Impact of comorbidity on the outcome of allogeneic hematopoietic stem cell transplantation in AML\/MDS patients [Abstract]","volume":"102","author":"Shahjahan","year":"2003","journal-title":"Blood"},{"issue":"11","key":"2019111718012635900_B39","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"2019111718012635900_B40","doi-asserted-by":"crossref","first-page":"324a","DOI":"10.1182\/blood.V104.11.1145.1145","article-title":"Clinical predictors of transplant related mortality after reduced intensity allogeneic stem cell transplantation (RIST) [Abstract]","volume":"104","author":"Pollyea","year":"2004","journal-title":"Blood"},{"issue":"8","key":"2019111718012635900_B41","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"27","key":"2019111718012635900_B42","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.2006.09.7865","article-title":"Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation","volume":"25","author":"Sorror","year":"2007","journal-title":"J Clin Oncol"},{"issue":"30","key":"2019111718012635900_B43","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2007.15.4757","article-title":"Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"26","author":"Sorror","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111718012635900_B44","doi-asserted-by":"crossref","first-page":"190a","DOI":"10.1182\/blood.V110.11.616.616","article-title":"Comorbidity, lactate dehydrogenase (LDH), and chemosensitivity are independent predictors of mortality after autologous hematopoietic cell transplantation (HCT) for patients (pts) with lymphoma [Abstract]","volume":"110","author":"Sorror","year":"2007","journal-title":"Blood"},{"key":"2019111718012635900_B45","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.23375","article-title":"Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation","volume":"112","author":"Sorror","year":"2008","journal-title":"Cancer"},{"issue":"20","key":"2019111718012635900_B46","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1182\/blood-2010-01-263624","article-title":"Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase","volume":"115","author":"Pavlu","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111718012635900_B47","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/bmt.2009.236","article-title":"Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML","volume":"45","author":"Lim","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"27","key":"2019111718012635900_B48","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1182\/blood-2009-03-213298","article-title":"Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"114","author":"Pagel","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2019111718012635900_B49","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/blood.V112.11.2994.2994","article-title":"A regimen of treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation (HCT) for high-risk hematologic malignancies is associated with low treatment-related mortality [Abstract]","volume":"112","author":"Nemecek","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2019111718012635900_B50","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1200\/JCO.2002.04.044","article-title":"Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study","volume":"20","author":"Kornblith","year":"2002","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111718012635900_B51","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/blood.V114.22.650.650","article-title":"Association between the Hematopoietic Cell Transplantation-Specific Comorbidity Index (CI) and non-relapse mortality (NRM) after reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) for acute myeloid leukemia (AML) in first complete remission (CR1) [Abstract]","volume":"114","author":"Mohty","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111718012635900_B52","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1365-2362.2008.02041.x","article-title":"Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation","volume":"38","author":"Boehm","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"2019111718012635900_B53","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.bbmt.2005.05.008","article-title":"Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia","volume":"11","author":"Kerbauy","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2019111718012635900_B54","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1182\/blood.V90.10.4201","article-title":"Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma","volume":"90","author":"Verdonck","year":"1997","journal-title":"Blood"},{"issue":"13","key":"2019111718012635900_B55","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2005-05-1778","article-title":"Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia","volume":"106","author":"Gribben","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2019111718012635900_B56","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2007-07-098483","article-title":"Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative regimens for treatment of lymphoma and chronic lymphocytic leukemia","volume":"111","author":"Sorror","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2019111718012635900_B57","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/leu.2009.1","article-title":"The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation","volume":"23","author":"Farina","year":"2009","journal-title":"Leukemia"},{"issue":"2","key":"2019111718012635900_B58","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbmt.2008.11.023","article-title":"Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Pollack","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111718012635900_B59","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbmt.2008.12.206","article-title":"Tandem autologous and nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) from HLA-matched related or unrelated donors for advanced lymphoma or chronic lymphocytic leukemia (CLL) [Abstract]","volume":"15","author":"Sorror","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2019111718012635900_B60","doi-asserted-by":"crossref","first-page":"98a","DOI":"10.1182\/blood.V108.11.316.316","article-title":"A phase II trial of 90Y-ibritumomab tiuxetan-based reduced intensity allogeneic peripheral blood stem cell (PBSC) transplantation for relapsed CD20+ B-cell non-Hodgkins lymphoma (NHL) [Abstract]","volume":"108","author":"Gopal","year":"2006","journal-title":"Blood"},{"key":"2019111718012635900_B61","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.1988.6.10.1562","article-title":"Regimen-related toxicity in patients undergoing bone marrow transplantation","volume":"6","author":"Bearman","year":"1988","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111718012635900_B62","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.bbmt.2008.06.019","article-title":"Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma","volume":"14","author":"Labont\u00e9","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"34","key":"2019111718012635900_B63","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1200\/JCO.2008.17.7428","article-title":"Late congestive heart failure after hematopoietic cell transplantation","volume":"26","author":"Armenian","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111718012635900_B64","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.bbmt.2009.06.001","article-title":"Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction","volume":"15","author":"Qazilbash","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2019111718012635900_B65","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.1998.16.4.1582","article-title":"Comorbidity and functional status are independent in older cancer patients","volume":"16","author":"Extermann","year":"1998","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111718012635900_B66","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.bbmt.2006.05.015","article-title":"Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation","volume":"12","author":"Artz","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2019111718012635900_B67","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/bmt.2008.300","article-title":"Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center","volume":"43","author":"Guilfoyle","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"8\u20139","key":"2019111718012635900_B68","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/0959-8049(92)90510-9","article-title":"Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group scoring scale and vice versa?","volume":"28A","author":"Verger","year":"1992","journal-title":"Eur J Cancer"},{"issue":"5","key":"2019111718012635900_B69","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.leu.2402905","article-title":"Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning","volume":"17","author":"Dreger","year":"2003","journal-title":"Leukemia"},{"key":"2019111718012635900_B70","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.1993.11.12.2342","article-title":"Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21 year Seattle experience","volume":"11","author":"Anderson","year":"1993","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111718012635900_B71","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.bbmt.2010.02.004","article-title":"Prognostic factor and quality of life analysis in 160 patients aged > or = to 60 years with hematologic neoplasias treated with allogeneic hematopoietic cell transplantation","volume":"16","author":"Deschler","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2019111718012635900_B72","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3324\/haematol.2009.011809","article-title":"A modifed EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia","volume":"95","author":"Terwey","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"2019111718012635900_B73","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.1984.2.3.187","article-title":"Karnofsky performance status revisited: reliability, validity, and guidelines","volume":"2","author":"Schag","year":"1984","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111718012635900_B74","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1182\/blood-2007-06-096966","article-title":"Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: Combined FHCRC and MDACC experiences","volume":"110","author":"Sorror","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2019111718012635900_B75","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbmt.2006.11.004","article-title":"Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia","volume":"13","author":"Kerbauy","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111718012635900_B76","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.bbmt.2009.06.011","article-title":"Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts","volume":"15","author":"Gyurkocza","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2019111718012635900_B77","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.bbmt.2007.04.004","article-title":"Comparable antileukemia\/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen","volume":"13","author":"Maruyama","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2019111718012635900_B78","first-page":"87","article-title":"Usefulness of hematopoietic cell transplantation-specific comorbidity index after allogeneic hematopoietic stem cell transplantation [Article in Japanese]","volume":"35","author":"Fujimaki","year":"2008","journal-title":"Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]"},{"issue":"3","key":"2019111718012635900_B79","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.bbmt.2007.12.488","article-title":"Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor","volume":"14","author":"Majhail","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2019111718012635900_B80","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1182\/blood.V112.11.4295.4295","article-title":"Pre-transplant comorbidity as an outcome predictor in hematopoietic cell transplantation for severe aplastic anemia [Abstract]","volume":"112","author":"Lim","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2019111718012635900_B81","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/bmt.2009.194","article-title":"Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study","volume":"45","author":"Kataoka","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2019111718012635900_B82","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.bbmt.2009.11.008","article-title":"Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut points to determine low, intermediate and high risk groups: the flexible HCT-CI is the best predictor of NRM and OS in a population of patients undergoing allo-RIC","volume":"16","author":"Barba","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019111718012635900_B83","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/leu.2009.1","article-title":"The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation","volume":"23","author":"Farina","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"2019111718012635900_B84","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/bmt.2009.236","article-title":"Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML","volume":"45","author":"Lim","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2019111718012635900_B85","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3324\/haematol.2008.002063","article-title":"The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome","volume":"94","author":"Zipperer","year":"2009","journal-title":"Haematologica"},{"issue":"1","key":"2019111718012635900_B86","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/annonc\/mdp258","article-title":"Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group","volume":"21","author":"Sperr","year":"2010","journal-title":"Ann Oncol"},{"issue":"4","key":"2019111718012635900_B87","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2141.2006.06476.x","article-title":"The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia","volume":"136","author":"Giles","year":"2007","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111718012635900_B88","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/hon.889","article-title":"Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients","volume":"27","author":"Breccia","year":"2009","journal-title":"Hematol Oncol"},{"issue":"9","key":"2019111718012635900_B89","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.bbmt.2008.06.008","article-title":"Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants","volume":"14","author":"Majhail","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2019111718012635900_B90","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.bbmt.2008.08.004","article-title":"Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation","volume":"14","author":"Artz","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111718012635900_B91","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2008.197","article-title":"Impact of comorbidity indexes on non-relapse mortality","volume":"22","author":"Xhaard","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"2019111718012635900_B92","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1042\/cs0420325","article-title":"Iron-deficiency anaemia: its effect on transfer factor for the lung (diffusiong capacity) and ventilation and cardiac frequency during sub-maximal exercise","volume":"42","author":"Cotes","year":"1972","journal-title":"Clin Sci"},{"issue":"6","key":"2019111718012635900_B93","first-page":"965","article-title":"The effect of anemia on pulmonary diffusing capacity with derivation of a correction equation","volume":"102","author":"Dinakara","year":"1970","journal-title":"Am Rev Respir Dis"},{"key":"2019111718012635900_B94","article-title":"Assignment of scores for the hematopoietic cell transplantation-comorbidity index: integer vs exact weights [Letter to the Editor]","author":"Sorror","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2019111718012635900_B95","doi-asserted-by":"crossref","first-page":"882A","DOI":"10.1182\/blood.V110.11.3005.3005","article-title":"C-reactive protein on admission predicts transplant-related mortality in recipients of allogeneic stem cell transplant [Abstract]","volume":"110","author":"Kew","year":"2007","journal-title":"Blood"},{"issue":"22","key":"2019111718012635900_B96","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1182\/blood.V114.22.651.651","article-title":"Low albumin, high ferritin, and thrombocytopenia before transplant predict non-relapse mortality (NRM) independent of the hematopoeitic cell transplantation comorbidity index (HCT-CI) [Abstract]","volume":"114","author":"Sorror","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2019111718012635900_B97","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1080\/10428190903144659","article-title":"Iron overload, hematopoietic cell transplantation, and graft-versus-host disease","volume":"50","author":"Deeg","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"2019111718012635900_B98","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jama.1994.03520130074036","article-title":"Serum albumin level and physical disability as predictors of mortality in older persons","volume":"272","author":"Corti","year":"1994","journal-title":"JAMA"},{"issue":"23","key":"2019111718012635900_B99","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1161\/01.CIR.0000042673.07632.76","article-title":"Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring Study","volume":"106","author":"Djousse","year":"2002","journal-title":"Circulation"},{"issue":"6","key":"2019111718012635900_B100","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1378\/chest.100.6.1619","article-title":"The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults","volume":"100","author":"Knaus","year":"1991","journal-title":"Chest"},{"issue":"6","key":"2019111718012635900_B101","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ctrv.2009.04.005","article-title":"Multidimensional geriatric evaluation for older cancer patients as a clinical and research tool","volume":"35","author":"Brunello","year":"2009","journal-title":"Cancer Treat Rev"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2010\/1\/237\/1492553\/bep00110000237.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2010\/1\/237\/1492553\/bep00110000237.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T18:04:52Z","timestamp":1592244292000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2010\/1\/237\/96390\/Comorbidities-and-Hematopoietic-Cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,4]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2010.1.237","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,4]]}}}